Walden IRB vs the partner site's IRB: when you need both, which goes first, and how to keep one file consistent
Two boards can review one study without either being redundant, because they are not doing the same job. The hospital's IRB answers for its patients, its staff, and its records; Walden's answers for the research conducted under its name — and its approval is the one no Walden project can begin without. Neither board reports to the other, which is why "which goes first" has no universal answer: the sequence falls out of the two boards' own policies, discovered early or discovered expensively. What is entirely in your control is the thing that sinks most dual reviews — drift. Two boards will each mark up the file, and unless one version remains the single source of truth, you end up conducting a study neither board actually approved.
You need the site's IRB when the site's own policy requires it — Walden's approval is required regardless. Sequencing comes from the two boards' rules, learned early through Form A and a call to the site. One protocol version, identical everywhere, keeps the file consistent.
When does the partner site's IRB have to review at all?
When the site says so. Hospitals and health systems, school districts, universities, and government agencies commonly maintain their own human-research protections, and an organization with its own IRB decides for itself what that board must see before research touches its people or its records. Nothing in Walden's approval reaches across that line: a letter from Walden's board permits the study as a Walden study; it does not oblige a hospital to open its doors. The reverse is equally true — a site IRB's blessing does not start a Walden project, because Walden requires its own review before any collection, full stop. So the first question is not regulatory but factual: does this organization have an IRB or research office, and what does its policy require of an outside study of this kind? Ask the site directly, early. Many organizations without any board of their own handle permission through a signed letter instead, which is a different instrument doing a different job — our guide to the letter of cooperation walks through that page.
Which board goes first?
Whichever the two boards' policies say — and the honest work is finding that out before it finds you. Some site IRBs will not open a file until the researcher's home institution has approved it; others review first and issue approval conditioned on Walden's; others accept parallel review. On Walden's side, the disclosure happens early by design: Form A describes your data sources and partner organizations, and Walden is explicit that the IRB tells you what documentation it needs after reading those answers — and that you should not hold your submission hostage to site paperwork nobody has requested yet. Walden's current handbook and IRB portal govern how its board treats a site's parallel review in your particular case; the site's research office governs its side. The desk's practice is unglamorous: ask both, in writing, at the start — then build the file to the stricter reading, so no sequencing surprise can send it back through a gate it already cleared. How those gates run on Walden's side is mapped in the step-by-step walk through Walden's IRB process.
Can one board rely on the other?
Sometimes, and never by your declaration. The federal framework for cooperative research — 45 CFR 46.114 — expects institutions engaged in multi-site work to guard against duplicated review, and it contemplates arrangements in which one board's reading serves more than one institution; formal reliance runs through written agreements between the institutions, not through a researcher's request. Whether any of that machinery applies to a single doctoral study at one partner site is a decision that belongs to the boards and offices involved, under their current policies. What you can usefully do is raise the question precisely: ask the site's research office whether it requires its own full review, will accept Walden's, or wants something lighter, and let Walden's IRB office see the answer. A file that documents who reviewed what, and on what authority, reads as a researcher in command of the arrangement — whatever the arrangement turns out to be.
What does each board actually read?
| Walden's IRB | The site's IRB | |
|---|---|---|
| Answers for | Research conducted under Walden's name, and the participants in it | The organization's patients, staff, learners, and records |
| Cares most about | The whole design: consent, recruitment, instruments, data security, dual roles, alignment with the approved proposal | Fit with its own policies: clinical operations, privacy obligations for its records, burden on its people, its liability |
| Issues | The approval letter with the number Walden expects cited in the completed study | Its own approval, a reliance or deferral decision, or written permission in another form |
| Cannot do | Grant you access to the site — that permission is the site's alone | Start the Walden study — no collection precedes Walden's approval |
| Hears about changes | Every amendment to the approved design, before it happens | Every amendment that touches its setting — the same change, told to both |
How does one file stay consistent in front of two boards?
By deciding, before anything is filed anywhere, that there is exactly one study — and policing it. Dual review multiplies documents but must never multiply designs. The desk's discipline runs:
- One protocol, one version marker. Both boards read the same protocol text. When either requires a change, the version increments once and every document downstream — both consents, all instruments, both applications — is swept to match before anything else moves.
- Instruments identical to the character. The survey the site IRB approved and the survey in the Walden file must be the same artifact, not siblings. Two "final" guides is how a study ends up conducted under neither approval.
- Consent that serves two masters visibly. Each board may require its own elements, contacts, or template language; build one consent that satisfies both where possible, and where the boards force separate documents, keep the study description word-for-word common so no participant was told two different studies.
- Letters that agree with the application. The classic dual-review failure is quiet contradiction: a site letter authorizing a records review while the Walden application also promises interviews, or a site approval naming one unit while recruitment materials name three. Every claim in every document must be true in every other — the board that spots the mismatch will return the file, and both boards will wait while you fix it. Records-based projects are especially prone to this, for the reasons in our piece on chart reviews and existing data.
- Amendments in stereo. After approval, a change accepted by one board and never told to the other reopens the exchange at the worst possible point — mid-collection. Both letters stay current or neither protects you.
Does the site's name appear in the finished study?
Almost always no — and the discipline extends past the chapters. Walden's editors put site confidentiality on the pre-review checklist for the narrative and back matter alike, acknowledgments and appendices included, and the Writing Center's guidance is to refer to organizations in general terms, redact identifying detail from anything attached, and leave out correspondence already sent to the IRB. In a dual-review study that instruction covers more paper than usual: two boards' letters, a reliance decision, site permissions — each carrying letterhead that can unmask what every other page conceals. The masking, like the study, has to be consistent to work.
What to do next
Whether the organization hosting your study runs a review board of its own is the single cheapest fact to learn early — and the costliest to discover late. Tell us the site, the design, and what its research office has said so far; a consultant will map both reviews, draft to the stricter reading, and carry the correspondence with each board until the letters agree. This practice is independent — affiliated with neither Walden University nor any site; the study stays yours, and each board decides for itself. Request the free application review, or see how the desk carries the whole exchange end to end.
Sources
- 45 CFR 46.114 — cooperative research, joint review, and reliance arrangements — law.cornell.edu/cfr/text/45/46.114
- Walden Quick Answers, common reasons for delays in ethics approval (Form A, partner organizations, written permission) — academicanswers.waldenu.edu/faq/343947
- Walden University Catalog & Handbook, Doctoral Learning and Resources (approval before any collection; the approval number in the completed study) — academics.waldenu.edu/handbook/learning-modalities/doctoral-research-resources
- Walden Quick Answers, collecting data in a clinical setting (pointer to the IRB's clinical-setting guidance) — academicanswers.waldenu.edu/faq/293504
- Walden Quick Answers, Form and Style webinar (site and participant confidentiality across chapters, acknowledgments, appendices) — academicanswers.waldenu.edu/faq/358654
- Walden Writing Center blog, Maintaining Confidentiality, parts 1 and 2 (masking organizations, redacting included letters) — waldenwritingcenter.blogspot.com (part 1) · (part 2)